Saturday, October 3, 2026

Nikkei 225 Bullish Momentum With A 4% Rise In The Last 5 Sessions

ViaNews Editorial Team

October 13, 2023

Nikkei 225 Bullish Momentum With A 4% Rise In The Last 5 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 4.33% for the last 5 sessions. At 21:08 EST on Thursday, 12 October, Nikkei 225 (N225) is $32,422.14.

About Nikkei 225's yearly highs and lows, it's 26.34% up from its 52-week low and 4% down from its 52-week high.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be oversold (<=20).

News about

  • According to Zacks on Wednesday, 11 October, "Avangrid declared a quarterly dividend of 44 cents per share in July 2023, resulting in an annual payout of $1.76.AGR's current dividend yield is 5.84%, better than the Zacks S&P 500 Composite's 1.73%."
  • According to DailyForex on Wednesday, 11 October, "In this context, the S&P 500 appears poised for a continued back-and-forth pattern, underscoring the importance of caution and astute risk management.", "In the end, the S&P 500 confronts a pivotal juncture, testing key resistance levels while contending with the reopening of the bond market. "
  • According to MarketWatch on Wednesday, 11 October, "Walmart's stock has gained 11% in the year to date, while the S&P 500 SPX has gained 13.5%."
  • According to MarketWatch on Wednesday, 11 October, "The stock has gained 8% in the year to date, while the S&P 500 has gained 13.5%."
  • According to MarketWatch on Wednesday, 11 October, "His first-hand experience leading through challenges and opportunities of a changing health care services continuum will help accelerate our integrated care strategy at pace." Humana stock has lost 2.3% year to date through Tuesday, while the Health Care Select Sector ETF has declined 3.5% and the S&P 500 has advanced 13.5%."

More news about Nikkei 225 (N225).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com